CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...